argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Financial Performance - Company reported $1.3 billion in global product net sales for the fourth quarter and $4.2 billion for the full year 2025, representing a 90% year-over-year growth [1][19] - Operating income reached $1.1 billion in 2025, marking the first year of operating profitability [1] - Profit for the year was $1.3 billion, compared to $833 million in 2024, with basic profit per share increasing to $21.08 from $13.92 [20][19] Product Development and Pipeline - VYVGART, the company's leading product, is approved for three indications, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [6][24] - Positive results from the Phase 3 ADAPT OCULUS study support the planned submission for expanding VYVGART's label into ocular myasthenia gravis (oMG) [3][6] - The company aims to treat 50,000 patients globally and secure 10 labeled indications across approved medicines by 2030 [5] Strategic Initiatives - Company is focused on expanding its FcRn portfolio and advancing multiple label expansions, including ongoing registrational studies in rheumatology [4][6] - The expected launch of the VYVGART SC autoinjector in 2027 and the progression of two next-generation FcRn candidates in 2026 are part of the growth strategy [12][26] - The company plans to have four Phase 3 molecules and a total of 10 molecules in clinical development by the end of 2026 [9][26] Market Impact - VYVGART has reached 19,000 patients globally, reinforcing the company's leadership in the myasthenia gravis market [4] - The company is advancing its pipeline with new first-in-class candidates from its Immunology Innovation Program, supporting long-term growth [4][9]